Pharma Mar SA Achieves Recruitment Milestone in Phase III Cancer Trial

Pharma Mar SA has announced a significant achievement in its phase III LAGOON clinical trial, having successfully recruited 705 patients. This trial is focused on evaluating the efficacy of Zepzelca® (lurbinectedin) in the treatment of small cell lung cancer. The recruitment of such a substantial number of participants marks a pivotal step forward in the company's efforts to expand treatment options for cancer patients. Preliminary results from the trial are anticipated to be released in early 2026. The study aims to assess both overall and progression-free survival rates, thereby contributing valuable insights to the ongoing research and development of advanced cancer therapies.